Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMuhammad Shaheer MannanMarshfield ClinicINIqra NadeemChildren's Hospital of PhiladelphiaHRHafsa Arshad Azam RajaRawalpindi Medical University

Discussion

Loading...

Member takes

Overview

Meta-analysis shows blinatumomab improves survival in pediatric B-ALL patients, suggesting better outcomes versus chemotherapy.

Key Points

  • To assess the impact of adding blinatumomab to chemotherapy on survival and MRD outcomes in pediatric B-ALL.
  • Conducted a meta-analysis of randomized controlled trials
  • Searched PubMed, EMBASE, and Cochrane Library
  • Included trials comparing blinatumomab and chemotherapy
  • Analyzed disease-free survival, overall survival, and adverse effects
  • Blinatumomab improved disease-free survival with a 37% reduction in recurrence (RR: 0.63)
  • Overall survival increased with a 38% reduction in mortality (RR: 0.62)
  • No significant improvement in MRD clearance (RR: 2.53)
  • Adverse effects were similar between groups, indicating safety concerns

Cite This Study

Mannan et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e5https://doi.org/10.1182/blood-2025-6867
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  2. 2Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  3. 3Blinatumomab for Pediatric High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia: Safety, MRD Response and Survival in a Single-Center Retrospective Cohort2026
  4. 4Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 1 citations
  5. 5Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024